Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy.

"Declarations Ethics approval and consent to participateThe underlying experiments were ethically approved by the local authorities. In particular, the isolation of melanoma cells from tumor tissue and the development of cell lines (PDSC) and patient-derived xenografts (PDX) were approved by the local ethics committee under license number 781/2018 BO2 and by the Regierungspräsidium under license number HT 7/18A. All animal studies with disulfiram were approved by the Regierungspräsidium Tübingen under license number HT01/20G. Competing interestsFMT, SP, SR, BS, NC, MK, MS, BM and OR have no competing interests. HN reports institutional funding from Novartis and Pierre-Fabre outside the submitted work. LF has/had advisory roles for Novartis, Sanofi, Philogen, and Bristol-Myers Squibb, all which took place outside the submitted work. TE is/was a consultant for Novartis, MSD, Merck, CureVac, Bristol-Myers Squibb, Sanofi, Immunocore, Pierre Fabre, Almirall Hermal. All out of the scope of this work. CG reports grants and personal fees from NeraCare, Novartis, Roche, Sanofi, personal fees from Amgen, BMS, MSD, and Philogen, all outside the submitted work. TA declares personal fees from CeCaVa, BMS, Novartis and Pierre Fabre and institutional grants from Novartis, Neracare, Sanofi, Novartis, Skyline-Dx, IO Biotech, MSD, University Hospital Essen, Roche and Unicancer all outside the submitted work. TS reports institutional funding from Novartis, Pascoe, Neracare and Skyline-Dx all outside the submitted work. Competing interests FMT, SP, SR, BS, NC, MK, MS, BM and OR have no competing interests. HN reports institutional funding from Novartis and Pierre-Fabre outside the submitted work. LF has/had advisory roles for Novartis, Sanofi, Philogen, and Bristol-Myers Squibb, all which took place outside the submitted work. TE is/was a consultant for Novartis, MSD, Merck, CureVac, Bristol-Myers Squibb, Sanofi, Immunocore, Pierre Fabre, Almirall Hermal. All out of the scope of this work. CG reports grants and personal fees from NeraCare, Novartis, Roche, Sanofi, personal fees from Amgen, BMS, MSD, and Philogen, all outside the submitted work. TA declares personal fees from CeCaVa, BMS, Novartis and Pierre Fabre and institutional grants from Novartis, Neracare, Sanofi, Novartis, Skyline-Dx, IO Biotech, MSD, University Hospital Essen, Roche and Unicancer all outside the submitted work. TS reports institutional funding from Novartis, Pascoe, Neracare and Skyline-Dx all outside the submitted work."

"Funding Open Access funding enabled and organized by Projekt DEAL. F.M.T. was supported by the National Council of Science and Technology of Mexico (CONACYT) and the Wilhelm-Schuler foundation at the Eberhard Karls Universität Tübingen. The project and T.A. were supported by the Novartis Melanoma Award for Young Academics (MAYA 2020)."